Having trouble accessing articles? Reset your cache.
FDA approved Gilenya fingolimod from Novartis AG (NYSE:NVS; SIX:NOVN) to treat relapsing forms of multiple sclerosis (MS). The approval includes a REMS on the safe use and possible risks of
Get a two-week free trial subscription to BioCentury